CARUGO - POMPILIO GROUP
The applied research activity of CERCA aims to understand pathogenesis and innovative diagnostic and therapeutic strategies for cardiovascular diseases, in particular heart failure of genetic or ischemic origin (with specific focus on regenerative medicine), for which conventional therapies are either not sufficient or not available.
The team is composed by Prof. Pompilio, Prof. Carugo, five physicians, one geneticist, one research staff, seven post-docs, two laboratory technicians and a clinical research assistant.
WHAT SERVICE DO WE OFFER?
Besides a solid experience in the diagnosis and treatment of heart diseases and cardiomyopathies, the group is involved in clinical and translational research.
Our projects are based on novel patient-specific cellular models, which allow the study of pathogenic alterations, underlying molecular mechanisms and constitute a cellular platform for drug screening. In addition to the use of primary cells, several human induced pluripotent-derived cell lines (hu iPSC) were produced and characterized, from which cardiomyocytes were obtained.
Patients constitute the starting and closing point of CERCA studies. For this reason, a complete clinical and genetic characterization of patients is important.
This is made possible through dedicated cardiomyopathy outpatient services, first and second level echocardiography as well as Magnetic Resonance Imaging.
A genetic diagnostic service for cardiomyopathies is also active with Next Generation Sequencing technology.
PUBLICATIONS CARUGO - POMPILIO GROUP
DONATION CARUGO - POMPILIO GROUP